Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 1/20 | 0.46 |
| ▸ | OXER1 | Q8TDS5 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | BUB1 | O43683 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 4/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.37 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.37 |
| ▸ | NQO2 | P16083 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | HTR6 | P50406 | 1/20 | 0.34 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1347686 | 0.89 | ACLY (0.44) | ACLYOXER1L3MBTL1BUB1BCHE | |
| SCHEMBL31370595 | 0.89 | ACLY (0.44) | ACLYOXER1L3MBTL1BUB1BCHE | |
| SCHEMBL29183522 | 0.88 | ACLY (0.46) | ACLYOXER1L3MBTL1BUB1BCHE | |
| SCHEMBL27839506 | 0.87 | ACLY (0.43) | ACLYOXER1L3MBTL1BUB1BCHE | |
| SCHEMBL1350891 | 0.87 | ACLY (0.43) | ACLYOXER1L3MBTL1BUB1BCHE | |
| SCHEMBL31370381 | 0.87 | ACLY (0.45) | ACLYOXER1L3MBTL1BUB1BCHE | |
| SCHEMBL1349273 | 0.82 | ACLY (0.47) | ACLYL3MBTL1BUB1BCHENR1H2 | |
| SCHEMBL30711258 | 0.82 | ACLY (0.47) | ACLYL3MBTL1BUB1BCHENR1H2 | |
| SCHEMBL2877952 | 0.81 | ACLY (0.47) | ACLYL3MBTL1BUB1BCHENR1H2 | |
| SCHEMBL16339898 | 0.81 | ACLY (0.54) | ACLYL3MBTL1BUB1BCHENR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1846410-B1 | DIHYDROQUINAZOLINONES AS 5HT MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2009-01-21 | — | — | EP | claimed |
| EP-1370561-B1 | TETRAHYDRO-PYRAZINO[1,2-A]INDOLES FOR THE TREATMENT OF CENTRAL NERVOUS DISORDERS | HOFFMANN LA ROCHE (CH) | 2009-02-11 | — | — | EP | disclosed |
| US-7253281-B2 | Anti-obesity 1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indoles | HOFFMANN-LA ROCHE INC. (US) | 2007-08-07 | — | — | US | disclosed |
| US-20070106076-A1 | Anti-obesity 1,2,3,4,10,10a-hexahydropyrazino [1,2-a] indoles | BENTLEY JONATHAN M | 2007-05-10 | — | — | US | disclosed |
| US-20050239789-A1 | Anti-obesity 1,2,3,4,10,10a-hexahydropyrazino[1,2-a] indoles | BENTLEY JONATHAN M | 2005-10-27 | — | — | US | disclosed |
| EP-1325008-B1 | PIPERAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2005-10-05 | — | — | EP | disclosed |
| US-6933387-B2 | Anti-obesity 1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indoles | HOFFMANN-LA ROCHE INC. (US) | 2005-08-23 | — | — | US | disclosed |
| US-6844345-B2 | Piperazine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2005-01-18 | — | — | US | disclosed |
| US-20030216401-A1 | Anti-obesity 1, 2, 3, 4, 10, 10a-hexahydropyrazino[1, 2-a] indoles | F. HOFFMANN-LA ROCHE AG (CH) | 2003-11-20 | — | — | US | disclosed |
| US-20020169163-A1 | Piperazine derivatives | HOFFMAN-LA ROCHE INC. | 2002-11-14 | — | — | US | disclosed |
| US-20020035110-A1 | Anti-obesity 1,2,3,4,10,10-a-hexahydropy razino [1,2-a] indoles | VERNALIS RESEARCH LIMITED, A BRITISH COMPANY (GB) | 2002-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239789-A1 | Anti-obesity 1,2,3,4,10,10a-hexahydropyrazino[1,2-a] indoles | GPR119, INSR, GIPR | ACLY 3340/4885OXER1 207/4885L3MBTL1 595/4885 |
| US-20030216401-A1 | Anti-obesity 1, 2, 3, 4, 10, 10a-hexahydropyrazino[1, 2-a] indoles | GPR119, INSR, IRS1 | ACLY 3090/4885OXER1 281/4885L3MBTL1 1048/4885 |
| US-20070106076-A1 | Anti-obesity 1,2,3,4,10,10a-hexahydropyrazino [1,2-a] indoles | GPR119, INSR, GIPR | ACLY 3340/4885OXER1 207/4885L3MBTL1 595/4885 |
| US-20020169163-A1 | Piperazine derivatives | GPR119, SLC5A2, DPP4 | ACLY 3040/4885OXER1 1251/4885L3MBTL1 3591/4885 |
| US-20020035110-A1 | Anti-obesity 1,2,3,4,10,10-a-hexahydropy razino [1,2-a] indoles | GPR119, HTR1D, HTR1A | ACLY 803/4885OXER1 603/4885L3MBTL1 1783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.